Panagora Asset Management Inc Lexicon Pharmaceuticals, Inc. Transaction History

Panagora Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $69,629 - $142,978	-53,152 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.95 - $3.89 $460,837 - $919,312	-236,327 Reduced 81.64%	53,152 $111,000
Q4 2021 Feb 10, 2022	BUY	$3.81 - $6.16 $1,238 - $2,002	325 Added 0.11%	289,479 $1.14 Million
Q3 2021 Nov 10, 2021	BUY	$3.38 - $5.35 $52,119 - $82,497	15,420 Added 5.63%	289,154 $1.39 Million
Q2 2021 Aug 11, 2021	BUY	$4.12 - $5.87 $419,667 - $597,924	101,861 Added 59.27%	273,734 $1.26 Million
Q1 2021 May 12, 2021	BUY	$3.45 - $9.09 $26,985 - $71,101	7,822 Added 4.77%	171,873 $1.01 Million
Q4 2020 Feb 10, 2021	BUY	$1.05 - $3.67 $497 - $1,739	474 Added 0.29%	164,051 $561,000
Q3 2020 Nov 13, 2020	BUY	$1.44 - $2.1 $156,346 - $228,005	108,574 Added 197.4%	163,577 $236,000
Q2 2020 Aug 12, 2020	SELL	$1.75 - $2.3 $131,458 - $172,773	-75,119 Reduced 57.73%	55,003 $110,000
Q1 2020 May 14, 2020	BUY	$1.8 - $4.28 $234,219 - $556,922	130,122 New	130,122 $254,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.